- OX124 is based on Orexo´s world-class drug delivery platform, amorphOX®, and is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl
- Synthetic opioids are behind 91 percent of all fatal opioid overdoses in the US[1]
- Prescription Drug User Fee Act date (PDUFA) set to
July 15, 2024 . If approved, US launch is expected to be initiated late 2024.
Uppsala,
OX124 will meet the growing need for more powerful medications to improve the possibility of reviving individuals experiencing an overdose caused by use of synthetic opioids, such as fentanyl, which today cause 91 percent of all fatal opioid overdoses.[2] OX124 is a potent medication and, in combination with rapid absorption and high bioavailability, this makes it capable of reversing an overdose or sustaining consciousness in a patient who has taken synthetic opioids. AmorphOX is an innovative powder-based technology that, in addition to rapid absorption and high bioavailability, improves stability and reduces sensitivity related to temperature changes. For users and lay-people[3] OX124 has the potential to become an efficient and reliable rescue medication independent of temperature variations during storage, for example its efficacy is not affected at freezing temperatures. OX124 is protected by patents until 2039.
Driven by the need to increase access to overdose medication, low-dose products, including the market leader, have recently been approved by the FDA as non-prescription over-the-counter (OTC) products. Historically, OTC products in the US have had limited reimbursement from insurance companies and, when applying similar industry analogues going forward, this may provide an advantage to high-dose prescription naloxone products, such as OX124. In addition, high-dose prescription products are expected to benefit from the continued expansion of mandatory co-prescription of naloxone when prescribing opioids to at-risk patients suffering from pain.
For further information please contact:
|
| ||
Tel: +46 (0)18 780 88 00 |
| Tel: +46 (0)18 780 88 00 |
|
E-mail: ir@orexo.com |
| E-mail: ir@orexo.com |
|
About
For more information about
The information was submitted for publication at
[1] Center of Disease Control and Prevention
[2] Center of Disease Control and Prevention
[3] E.g., police officers, prison personnel, family, and relatives
https://news.cision.com/orexo/r/orexo-announces-fda-acceptance-of-new-drug-application-filing-for-ox124--a-high-dose-rescue-medicati,c3883673
https://mb.cision.com/Main/694/3883673/2457111.pdf
https://news.cision.com/orexo/i/ox124-device-red-l-vial,c3243394
(c) 2023 Cision. All rights reserved., source